Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.
Akorn says the completed divestment of its branded ophthalmic portfolio to Théa Pharma will enable the firm to focus on growth areas including human generics and animal care.
Financial details were not revealed of the transaction, which follows Akorn going through Chapter 11 bankruptcy proceedings and a sale...
Create an account to read this article
Already a subscriber?
Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.
Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.
Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.
Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.
Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.
Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.
Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.
